EUROPE ANIMAL HEALTHCARE MARKET ANALYSIS

Europe Animal Healthcare Market, By Drug Type (Anti-Infective Agents, Anti-Inflammatory & Analgesic Agents, Parasiticides, Vaccines, Hormones & Substitutes, and Others), By Animal Type (Livestock (Bovine, Porcine, Poultry, and Other), Companion (Canine, Feline, Equine), By Indication (Infectious Diseases, Pain Management, Auto-immune Disease, and Others)

Published In : Apr 2024
Code : CMI550
Pages :195
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Concentration and Competitive Landscape

Europe Animal Healthcare Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Increasing Mutual Recognition Agreement among Regulatory Authorities

Increasing mutual recognition agreement among regulatory authorities for the inspections of animal healthcare drugs is expected to drive the Europe animal healthcare market growth over the forecast period. For instance, in June 2023, the U.S. Food and Drug Administration and European Medicines Agency announced a U.S.-EU Mutual Recognition Agreement (MRA) for pharmaceutical good manufacturing practices inspections of animal drugs. By extending coverage to animal drug manufacturers, the FDA will be able to rely on inspection reports created by certain European authorities minimizing the need for additional animal drug facility inspections and freeing up regulatory resources. The MRA extends only to surveillance inspections of drug establishments, not to pre-approval inspections.

Key Players Insights